Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Humacyte, Inc.NASDAQ: HUMA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.79M fell 2.3% year over year, behind the +0.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at -3.6% a year.
Context
- Depreciation & amortization amounted to 360.4% of revenue in FY2025.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.3% toward the trailing-twelve-month pace of +0.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 7.35M USD
- Year-over-year change
- +2.2%
- 4-year CAGR
- -2.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.35M | +2.2% |
| FY2024 | 2024-12-31 | 7.19M | -6.9% |
| FY2023 | 2023-12-31 | 7.72M | -6.0% |
| FY2022 | 2022-12-31 | 8.21M | -0.4% |
| FY2021 | 2021-12-31 | 8.24M | — |
Depreciation & Amortization vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 depreciation & amortization of $7.3M is the 2nd highest of the 11 companies compared; the peer median is $1.79M.
- Its year-over-year change of +0.4% is the 3rd highest of 10, against a peer median of -10.3%.
- Depreciation & amortization amounts to 362.3% of revenue for HUMA, versus a peer median of 6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.46M | +95.4% | +63.4% | 6.2% | |
| LTM Mar 2026 | $7.3M | +0.4% | -3.6% | 362.3% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $3.98M | -12.6% | -13.1% | 10.9% | |
| LTM Mar 2026 | $2.88M | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | $2.79M | -10.3% | +0.1% | 9.9% | |
| LTM Mar 2026 | $786.79K | +70.5% | +36.1% | — | |
| LTM Mar 2026 | $416K | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $284K | -92.5% | -39.2% | 4.9% | |
| LTM Mar 2026 | $224K | -4.3% | -1.1% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding HUMA) | $1.79M | -10.3% | +17.0% | 6.4% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.26M | 1.57M | 0 | 0 | 2.04M |
| Cost of Revenue | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M |
| Gross Profit | (60.08M) | (6.69M) | (76.55M) | (7.19M) | (15.01M) |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| Research & Development | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M |
| Selling, General & Admin | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M |
| Operating Expenses | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 7.35M |
| EBITDA | (13.89M) | 2.45M | (96.46M) | (132.23M) | (22.24M) |
| EBITDA Margin | -1099.6% | 156.2% | — | — | -1091.2% |
| Operating Income | (81.21M) | (84.58M) | (100.05M) | (114.4M) | (107.44M) |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Income | 16K | 2.63M | 5.47M | 4.1M | 2.59M |
| Interest Expense | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M |
| Other Income / Expenses | 54.73M | 72.61M | (10.73M) | (34.3M) | 66.6M |
| Income Before Tax | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Pre-Tax Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Basic) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| EPS (Diluted) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| Weighted Avg Shares | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
| Weighted Avg Shares (Diluted) | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.